Cerus Corporation (CERS)
Stock Price:
$5.91 USD
-0.34 (-5.44%)
Updated November 24, 2:59 PM EST - Market open
Key Info
| Market Cap |
987.81M |
| Revenue (ttm) |
107.15M |
| Net Income (ttm) |
-62.40M |
| Shares Out |
167.14M |
| EPS (ttm) |
-0.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 24 |
| Last Price |
$5.91 |
| Previous Close |
$6.25 |
| Change ($) |
-0.34 |
| Change (%) |
-5.44% |
| Day's Open |
6.27 |
| Day's Range |
5.90 - 6.31 |
| Day's Volume |
982,156 |
| 52-Week Range |
2.71 - 7.94 |
More Stats
| Market Cap |
987.81M |
| Enterprise Value |
913.81M |
| Earnings Date (est) |
Mar 9, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
167.14M |
| Float |
163.34M |
| EPS (basic) |
-0.39 |
| EPS (diluted) |
-0.40 |
| FCF / Share |
-0.26 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.49M |
| Short Ratio |
7.59 |
| Short % of Float |
6.42% |
| Beta |
1.24 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.22 |
| PB Ratio |
9.53 |
| Revenue |
107.15M |
| Operating Income |
-60.40M |
| Net Income |
-62.40M |
| Free Cash Flow |
-42.47M |
| Net Cash |
74.00M |
| Net Cash / Share |
0.44 |
| Gross Margin |
48.71% |
| Operating Margin |
-56.37% |
| Profit Margin |
-58.20% |
| FCF Margin |
-39.64% |
| ROA |
-19.98% |
| ROE |
-73.39% |
| ROIC |
-31.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.10*
(53.98% upside)
Low
8.00
Current: $5.91
High
10.00
Target: 9.10
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 93.77 | 76.05 | 51.33 | 39.28 | 34.22 | 36.42 | 39.66 | 36.70 | 30.60 | 21.68 |
| Revenue Growth | 23.3% | 48.17% | 30.68% | 14.76% | -6.02% | -8.17% | 8.07% | 19.91% | 41.17% | - |
| Gross Profit | 60.36 | 44.42 | 28.80 | 18.98 | 10.76 | 15.23 | 17.06 | 16.08 | 12.07 | 9.63 |
| Operating Income | -66.23 | -54.99 | -57.53 | -61.45 | -61.08 | -44.50 | -28.30 | -17.39 | -18.37 | -17.39 |
| Net Income | -71.24 | -57.56 | -60.59 | -62.91 | -55.87 | -38.76 | -43.34 | -15.92 | -16.98 | -16.91 |
| Shares Outstanding | 140 | 132 | 108 | 102 | 96.07 | 74.77 | 67.57 | 54.52 | 48.05 | 40.30 |
| Earnings Per Share | -0.51 | -0.44 | -0.56 | -0.62 | -0.61 | -0.61 | -0.64 | -0.33 | -0.35 | -0.42 |
| Operating Cash Flow | -65.84 | -31.25 | -52.24 | -53.53 | -51.13 | -39.81 | -26.66 | -13.92 | -15.63 | -14.27 |
| Capital Expenditures | -8.94 | -1.14 | -0.35 | -0.56 | -0.72 | -2.08 | -0.66 | -0.08 | -0.16 | -1.69 |
| Free Cash Flow | -74.77 | -32.39 | -52.59 | -54.09 | -51.85 | -41.89 | -27.33 | -14.00 | -15.79 | -15.96 |
| Cash & Equivalents | 88.15 | 120 | 60.94 | 71.81 | 108 | 51.80 | 57.98 | 27.00 | 26.09 | 30.31 |
| Total Debt | 64.45 | 29.87 | 29.80 | 19.38 | 19.80 | 9.87 | 3.37 | 7.72 | 7.22 | 4.89 |
| Net Cash / Debt | 23.70 | 90.44 | 31.15 | 52.44 | 88.69 | 41.93 | 54.62 | 19.28 | 18.87 | 25.42 |
| Assets | 166 | 163 | 98.24 | 103 | 139 | 81.78 | 83.38 | 48.92 | 45.37 | 48.17 |
| Liabilities | 108 | 78.94 | 59.30 | 45.69 | 44.64 | 40.26 | 40.59 | 29.81 | 27.05 | 24.44 |
| Book Value | 57.05 | 84.52 | 38.94 | 57.79 | 94.77 | 41.52 | 42.80 | 19.11 | 18.31 | 23.73 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cerus Corporation |
| Country |
United States |
| Employees |
254 |
| CEO |
William Mariner Greenman |
Stock Information
| Ticker Symbol |
CERS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CERS |
| IPO Date |
January 30, 1997 |
Description
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.